Breast Cancer Diagnostic Products
Breast cancer is the most common cancer in women worldwide, with nearly 2.3 million new cases and nearly 685,000 deaths in 2020. In 2021, the global breast cancer diagnostic products market (including imaging, biopsy, and sample testing products) was valued at approximately $4.9bn. Market drivers include the increasing global incidence of breast cancer due to a combination of behavioral factors and the aging of the population, increasing awareness regarding the importance of personalized breast cancer screening, the development of advanced imaging technologies, and increased use of advanced technologies such as gene expression and liquid biopsy. Limiters of the market include difficulties around reimbursement and cost containment, the lack of population-based screening programs in many countries, and the limitation of sales of traditional screening products as more advanced technologies gain market share. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for breast cancer diagnostic products; these include mammography systems (film-screen, full field digital mammography, and digital breast tomosynthesis systems as well as computer-aided detection software sold with mammography devices), automated breast ultrasound systems, magnetic resonance imaging coils, biopsy systems (biopsy guidance consoles and consumables, as well as minimally invasive biopsy systems), and sample testing systems (tumor marker tests, HER2 amplification status tests, gene expression profiling tests, and liquid biopsy tests for minimal residual disease). Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2021–26.
Related Medtech Insight articles: